Skip to Content
Merck
All Photos(1)

Key Documents

MAB858-2

Sigma-Aldrich

Anti-RSV Antibody, glycoprotein, all type A, B strains, clone 131-2G

clone 131-2G, from mouse

Synonym(s):

RSV

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

biological source

mouse

Quality Level

antibody form

purified immunoglobulin

antibody product type

primary antibodies

clone

131-2G, monoclonal

species reactivity

human

manufacturer/tradename

Chemicon®

technique(s)

ELISA: suitable
immunofluorescence: suitable

isotype

IgG1κ

shipped in

wet ice

General description

RSV is a labile paramyxovirus that produces a characteristic fusion of human cells in tissue culture--the syncytial effect. Two subtypes, A and B, have been identified. Subtype B are characterized as the asymptomatic strains of the virus. The more severe clinical illnesses involve Subtype A strains.

Specificity

Glycoprotein, 89 kD. Recognizes both A and B strains.

Immunogen

A2
Epitope: some type B strains

Application

Detect Respiratory Syncytial Virus using this Anti-RSV Antibody, glycoprotein, all type A, B strains, clone 131-2G validated for use in ELISA & IF.
ELISA

Indirect Immunofluorescence (fresh frozen tissue sections)

Final working dilutions must be determined by end user.
Research Category
Infectious Diseases
Research Sub Category
Infectious Diseases - Viral

Physical form

Format: Purified
Purified immunoglobulin. 1 mg/mL in 0.02M PB with 0.25M NaCl, pH=7.6 containing 0.1% sodium azide.

Storage and Stability

Maintain at 2 to 8° C in aliquots for up to 12 months after date of receipt. Do not store in diluted format.

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

10 - Combustible liquids

WGK

WGK 2

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Exploratory Spatial Analysis of in vitro Respiratory Syncytial Virus Co-infections.
Simeonov, I; Gong, X; Kim, O; Poss, M; Chiaromonte, F; Fricks, J
Viruses null
Myra N Widjojoatmodjo et al.
Virology journal, 7, 114-114 (2010-06-08)
Respiratory syncytial virus (RSV) is a primary cause of serious lower respiratory tract illness for which there is still no safe and effective vaccine available. Using reverse genetics, recombinant (r)RSV and an rRSV lacking the G gene (DeltaG) were constructed
Edgar R Wood et al.
The Journal of biological chemistry, 290(32), 19681-19696 (2015-06-10)
2',5'-Oligoadenylate synthetase (OAS) enzymes and RNase-L constitute a major effector arm of interferon (IFN)-mediated antiviral defense. OAS produces a unique oligonucleotide second messenger, 2',5'-oligoadenylate (2-5A), that binds and activates RNase-L. This pathway is down-regulated by virus- and host-encoded enzymes that
Caixia Su et al.
NPJ vaccines, 7(1), 168-168 (2022-12-20)
Respiratory syncytial virus (RSV) infection in children is the most common viral respiratory infection and can cause severe lung damage or death. There is no licensed vaccine for preventing RSV infection. Previously we demonstrated that an RSV vaccine, BARS13, consisting
Ana M Nuñez Castrejon et al.
Journal of virology, 96(7), e0220121-e0220121 (2022-03-11)
Respiratory syncytial virus (RSV) is a leading cause of severe lower respiratory tract disease of children, the elderly, and immunocompromised individuals. Currently, there are no FDA-approved RSV vaccines. The RSV G glycoprotein is used for viral attachment to host cells

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service